CA2406755A1 - A gene therapy system and method using alpha-msh and its derivatives - Google Patents

A gene therapy system and method using alpha-msh and its derivatives Download PDF

Info

Publication number
CA2406755A1
CA2406755A1 CA002406755A CA2406755A CA2406755A1 CA 2406755 A1 CA2406755 A1 CA 2406755A1 CA 002406755 A CA002406755 A CA 002406755A CA 2406755 A CA2406755 A CA 2406755A CA 2406755 A1 CA2406755 A1 CA 2406755A1
Authority
CA
Canada
Prior art keywords
msh
gene therapy
derivatives
gene
alpha
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA002406755A
Other languages
English (en)
French (fr)
Inventor
Anna P. Catania
James M. Lipton
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Individual
Original Assignee
Zengen Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zengen Inc filed Critical Zengen Inc
Publication of CA2406755A1 publication Critical patent/CA2406755A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Diabetes (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
CA002406755A 2000-04-28 2001-04-27 A gene therapy system and method using alpha-msh and its derivatives Abandoned CA2406755A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US20028700P 2000-04-28 2000-04-28
US60/200,287 2000-04-28
PCT/US2001/013826 WO2001082699A1 (en) 2000-04-28 2001-04-27 A gene therapy system and method using alpha-msh and its derivatives

Publications (1)

Publication Number Publication Date
CA2406755A1 true CA2406755A1 (en) 2001-11-08

Family

ID=22741073

Family Applications (1)

Application Number Title Priority Date Filing Date
CA002406755A Abandoned CA2406755A1 (en) 2000-04-28 2001-04-27 A gene therapy system and method using alpha-msh and its derivatives

Country Status (6)

Country Link
EP (1) EP1280409A4 (ja)
JP (1) JP2004509065A (ja)
CN (1) CN1429073A (ja)
AU (1) AU2001257420A1 (ja)
CA (1) CA2406755A1 (ja)
WO (1) WO2001082699A1 (ja)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106905432B (zh) * 2015-12-18 2018-12-21 兰州大学 一种α促黑素细胞激素的融合蛋白及其制备方法和应用

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5532347A (en) * 1992-04-10 1996-07-02 State Of Oregon, Acting By And Through The Oregon State Board Of Higher Education On Behalf Of The Oregon Health Sciences University, A Non-Profit Organization DNA encoding α melanocyte stimulating hormone receptor
US5744304A (en) * 1995-05-30 1998-04-28 Board Of Regents, The University Of Texas System Inflammation-induced expression of a recombinant gene
ATE348155T1 (de) * 1996-11-20 2007-01-15 Introgen Therapeutics Inc Ein verbessertes verfahren zur produktion und reinigung von adenoviralen vektoren
EP1137340A4 (en) * 1998-12-09 2005-12-21 Eleanor Roosevelt Inst COMPOSITION AND METHOD FOR REGULATING BODY WEIGHT AND ASSOCIATED CONDITIONS
EP1150570B1 (en) * 1999-01-22 2006-07-12 The Schepens Eye Research Institute, Inc. Activation of regulatory t cells by alpha-melanocyte stimulating hormone
AU7593001A (en) * 2000-07-14 2002-01-30 Zycos Inc Alpha-msh related compounds and methods of use

Also Published As

Publication number Publication date
AU2001257420A1 (en) 2001-11-12
EP1280409A1 (en) 2003-02-05
CN1429073A (zh) 2003-07-09
JP2004509065A (ja) 2004-03-25
EP1280409A4 (en) 2004-05-19
WO2001082699A1 (en) 2001-11-08

Similar Documents

Publication Publication Date Title
EP3453401A1 (en) Interleukin combination and use thereof
ES2690147T3 (es) Apelina pegilada y usos de la misma
CN105008395B (zh) 长效单链胰岛素类似物
CA2692358A1 (en) Recombinant human interferon-like proteins
CA2786090A1 (en) Interferon analogs
ES2712805T3 (es) Productos farmacéuticos antiinflamatorios
CA2748392C (en) Use of interleukin-22 for the prevention and/or treatment of multiple organ dysfunction syndrome (mods)
CN111040021B (zh) 一种改善生物活性蛋白性质的载体蛋白
CA2406755A1 (en) A gene therapy system and method using alpha-msh and its derivatives
TR201807891T4 (tr) Fibroz ve karaciğer hastalıklarının tedavi edilmesi.
US20040110696A1 (en) Gene therapy system and method using alpha-msh and its derivatives
EP3385285B1 (en) Fusion protein for á melanocyte stimulating hormone and preparation method and use thereof
JP2016508517A (ja) インスリン分泌性ポリペプチド
US20030108523A1 (en) Cancer treatment system
EA038673B1 (ru) Плазмидная днк, кодирующая дефенсин hnp-1, либо hnp-2, либо hnp-3
DK2618830T3 (en) Formulations to a kvæggranulocytkolonistimulerende factor and variants thereof
US5440022A (en) Hepatokine and methods for its use
US11633456B2 (en) Compositions and methods for promoting hair growth
US20230322872A1 (en) Recombinant protein comprising multiple multi-peptide sets, pharmaceutical composition comprising the recombinant protein, and method for preparing the recombinant protein
WO2024110757A1 (en) Control of nanocage self-assembly
WO2007037514A1 (ja) ヘパリン結合性上皮増殖因子様増殖因子の新規医薬用途
KR20230039143A (ko) 경피 약물전달 효능 및 지방 분해능이 향상된 펩타이드
KR20240035722A (ko) 세포 내 형질주입을 위한 신규한 폴리펩타이드 조성물
WO2021165841A1 (en) Compound for the treatment of a glycogenosis
FR2899589A1 (fr) Variants ameliores de l'interferon-gamma humain (ifn gamma)

Legal Events

Date Code Title Description
FZDE Dead